The effects of the nitric oxide donor SIN-1 on ischemia-reperfused cutaneous and myocutaneous flaps.
Ischemia-reperfusion injury causes tissue damage that leads to a decrease in bioavailability of nitric oxide. The authors hypothesized that an exogenous supply of nitric oxide will have beneficial effects on survival of skin and skeletal muscle subjected to ischemia-reperfusion injury. By using the nitric oxide donor SIN-1 (3-morpholino-sydnonimine) the effects of direct intraarterial infusion of an exogenous source of nitric oxide in reperfused flaps was studied. Bilateral island buttock skin flaps and latissimus dorsi myocutaneous flaps were elevated in eight pigs, for a total of 32 flaps. Flaps were subjected to 6 hours of ischemia followed by 18 hours of reperfusion. Flaps on one side of each animal were randomized to be treated with the nitric oxide donor (treatment group). The contralateral side was treated with an equivalent volume of saline vehicle (infusion control) SIN-1, or saline was administered as a continuous direct intraarterial infusion at the onset of reperfusion and continued during the observation period. Outcomes measured were tissue neutrophil accumulation by using myeloperoxidase assay and tissue survival (intravenous fluorescein and nitroblue tetrazolium for skin and muscle, respectively). In both skin and myocutaneous flaps, SIN-1 treatment caused a significant improvement in survival and a decrease in neutrophil accumulation. Nitric oxide may play an important role in the pathophysiologic process of ischemia-induced reperfusion injury in skin and skeletal muscle. Nitric oxide donors may be a promising family of therapeutic agents for the prevention of ischemia-induced reperfusion injury in cutaneous and myocutaneous flaps.
Khiabani
Kayvan T
KT
Microsurgical Research Laboratories, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
Kerrigan
Carolyn L
CL
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000473:pathology*; D013524:Surgical Flaps / Q000098:blood supply* / Q000473:pathology; D013552:Swine
D020030:Nitric Oxide Donors; C002385:linsidomine; D008981:Molsidomine